Schizophrenia.com

Reduction of deficit syndrome (Negative Symptoms) of schizophrenia by norepinephrine reuptake inhibitor

Negative symptoms are a significant barrier to successful functional outcome and recovery in individuals with schizophrenia and their management is not unproblematic. Reboxetine is a norepinephrine reuptake inhibitor (NRI)

RESULTS:

According to the findings, 76% of patients in the target group showed some positive response to reboxetine compared with 24% in the control group .

CONCLUSION:

Reboxetine, as an adjuvant to haloperidol, may have a helpful effect on the deficit syndrome of schizophrenia.

More info:

Source:

2 Likes